{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:27:17Z","timestamp":1789874837031,"version":"4.0.1"},"reference-count":237,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.blre.2019.100593","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T11:38:11Z","timestamp":1564054691000},"page":"100593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"special_numbering":"C","title":["Review of current transfusion therapy and blood banking practices"],"prefix":"10.1016","volume":"38","author":[{"given":"Emily K.","family":"Storch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Custer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay E.","family":"Menitove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Mintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.blre.2019.100593_bb0005","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/trf.14165","article-title":"Continued decline in blood collection and transfusion in the United States-2015","volume":"57","author":"Ellingson","year":"2017","journal-title":"Transfusion"},{"issue":"12","key":"10.1016\/j.blre.2019.100593_bb0010","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1111\/trf.14370","article-title":"Demographic and epidemiologic characterization of transfusion recipients from four US regions: evidence from the REDS-III recipient database","volume":"57","author":"Karafin","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2019.100593_bb0015","series-title":"Healthcare cost and utilization project (HCUP) statistical briefs","article-title":"Trends in hospitalizations with a red blood cell transfusion, 2000\u20132013: statistical brief #215","author":"West","year":"2016"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1017\/S0025727300040138","article-title":"The first human blood transfusion","volume":"24","author":"Farr","year":"1980","journal-title":"Med Hist"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1017\/S0025727300051383","article-title":"Blood group serology \u2013 the first four decades (1900\u20131939)","volume":"23","author":"Farr","year":"1979","journal-title":"Med Hist"},{"key":"10.1016\/j.blre.2019.100593_bb0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1537-2995.1961.tb00005.x","article-title":"On agglutination of normal human blood","volume":"1","author":"Landsteiner","year":"1961","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2019.100593_bb0035","first-page":"1011","article-title":"Anesthesia in cases of poor surgical risk. Some suggestions for decreasing the risk","volume":"74","author":"Adams","year":"1942","journal-title":"Surg Gynecol Obstet"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/bja\/aeh290","article-title":"Allogeneic red blood cell transfusions: efficacy, risks, alternatives and indications","volume":"95","author":"Madjdpour","year":"2005","journal-title":"Br J Anaesth"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0045","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1423-0410.2009.01223.x","article-title":"Red blood cell transfusion in the treatment and management of anaemia: the search for the elusive transfusion trigger","volume":"98","author":"Wang","year":"2010","journal-title":"Vox Sang"},{"key":"10.1016\/j.blre.2019.100593_bb0050","article-title":"Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion","volume":"10","author":"Carson","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb0055","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.hoc.2016.01.001","article-title":"Red blood cell transfusion strategies in adult and pediatric patients with malignancy","volume":"30","author":"Roubinian","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0060","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/trf.14436","article-title":"Surveys of blood collection and utilization","volume":"58","author":"Whitaker","year":"2018","journal-title":"Transfusion"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2019.100593_bb0065","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/trf.14168","article-title":"Supplemental findings from the National Blood Collection and Utilization Surveys, 2013 and 2015","volume":"57","author":"Sapiano","year":"2017","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0070","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1213\/ANE.0000000000003336","article-title":"Changes in international normalized ratios after plasma transfusion of varying doses in unique clinical environments","volume":"127","author":"Warner","year":"2018","journal-title":"Anesth Analg"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0075","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1213\/ANE.0000000000003505","article-title":"The mythology of plasma transfusion","volume":"127","author":"Waters","year":"2018","journal-title":"Anesth Analg"},{"issue":"9","key":"10.1016\/j.blre.2019.100593_bb0080","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/trf.13676","article-title":"Trends in United States blood collection and transfusion: results from the 2013 AABB blood collection, utilization, and patient blood management survey","volume":"56","author":"Whitaker","year":"2016","journal-title":"Transfusion"},{"issue":"13","key":"10.1016\/j.blre.2019.100593_bb0085","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra1612789","article-title":"Indications for and adverse effects of red-cell transfusion","volume":"377","author":"Carson","year":"2017","journal-title":"N Engl J Med"},{"issue":"9585","key":"10.1016\/j.blre.2019.100593_bb0090","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0140-6736(07)61197-0","article-title":"Red blood cell transfusion in clinical practice","volume":"370","author":"Klein","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0095","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1537-2995.1980.20280169958.x","article-title":"An analysis of blood transfusion of surgical patients by sex: a question for the transfusion trigger","volume":"20","author":"Friedman","year":"1980","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2019.100593_bb0100","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ahj.2018.04.007","article-title":"Clinical trials evaluating red blood cell transfusion thresholds: an updated systematic review and with additional focus on patients with cardiovascular disease","volume":"200","author":"Carson","year":"2018","journal-title":"Am Heart J"},{"issue":"8","key":"10.1016\/j.blre.2019.100593_bb0105","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.amjcard.2011.06.014","article-title":"Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT Randomized Pilot Study)","volume":"108","author":"Cooper","year":"2011","journal-title":"Am J Cardiol"},{"issue":"16","key":"10.1016\/j.blre.2019.100593_bb0110","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa066240","article-title":"Transfusion strategies for patients in pediatric intensive care units","volume":"356","author":"Lacroix","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2019.100593_bb0115","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1403612","article-title":"Liberal or restrictive transfusion after cardiac surgery","volume":"372","author":"Murphy","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.blre.2019.100593_bb0120","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1056\/NEJMoa1707572","article-title":"Age of red cells for transfusion and outcomes in critically ill adults","volume":"377","author":"Cooper","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.blre.2019.100593_bb0125","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/eurheartj\/ehy435","article-title":"Restrictive compared with liberal red cell transfusion strategies in cardiac surgery: a meta-analysis","volume":"40","author":"Shehata","year":"2019","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1211801","article-title":"Transfusion strategies for acute upper gastrointestinal bleeding","volume":"368","author":"Villanueva","year":"2013","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.blre.2019.100593_bb0135","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1711818","article-title":"Restrictive or liberal red-cell transfusion for cardiac surgery","volume":"377","author":"Mazer","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100593_bb0140","doi-asserted-by":"crossref","first-page":"i1351","DOI":"10.1136\/bmj.i1351","article-title":"Effect of restrictive versus liberal transfusion strategies on outcomes in patients with cardiovascular disease in a non-cardiac surgery setting: systematic review and meta-analysis","volume":"352","author":"Docherty","year":"2016","journal-title":"BMJ"},{"issue":"13","key":"10.1016\/j.blre.2019.100593_bb0145","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1056\/NEJMoa1808561","article-title":"Six-month outcomes after restrictive or liberal transfusion for cardiac surgery","volume":"379","author":"Mazer","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb0150","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.ahj.2013.03.001","article-title":"Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease","volume":"165","author":"Carson","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.blre.2019.100593_bb0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M17-3253","article-title":"Long-term outcomes among patients discharged from the hospital with moderate anemia: a retrospective cohort study","volume":"170","author":"Roubinian","year":"2018","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.blre.2019.100593_bb0160","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/PTS.0000000000000138","article-title":"Magnitude of anemia at discharge increases 30-day hospital readmissions","volume":"13","author":"Koch","year":"2017","journal-title":"J Patient Saf"},{"key":"10.1016\/j.blre.2019.100593_bb0165","article-title":"Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support","volume":"1","author":"Estcourt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb0170","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1042\/BJ20120675","article-title":"Erythrocyte storage increases rates of NO and nitrite scavenging: implications for transfusion-related toxicity","volume":"446","author":"Stapley","year":"2012","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0175","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.transci.2010.05.009","article-title":"Red cell changes during storage","volume":"43","author":"Hess","year":"2010","journal-title":"Transfus Apher Sci"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb0180","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/j.1537-2995.2010.02674.x","article-title":"The red blood cell storage lesion: a method to the madness","volume":"50","author":"Glynn","year":"2010","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0185","first-page":"82","article-title":"Red blood cell storage: the story so far","volume":"8","author":"D'Alessandro","year":"2010","journal-title":"Blood Transfus"},{"key":"10.1016\/j.blre.2019.100593_bb0190","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/asheducation-2011.1.475","article-title":"Vascular effects of the red blood cell storage lesion","volume":"2011","author":"Roback","year":"2011","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.blre.2019.100593_bb0195","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1537-2995.2011.03094.x","article-title":"Insufficient nitric oxide bioavailability: a hypothesis to explain adverse effects of red blood cell transfusion","volume":"51","author":"Roback","year":"2011","journal-title":"Transfusion"},{"issue":"11","key":"10.1016\/j.blre.2019.100593_bb0200","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/j.1537-2995.2006.01026.x","article-title":"Clinical consequences of red cell storage in the critically ill","volume":"46","author":"Tinmouth","year":"2006","journal-title":"Transfusion"},{"issue":"23","key":"10.1016\/j.blre.2019.100593_bb0205","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1001\/jama.2015.13977","article-title":"Effect of transfusion of red blood cells with longer vs shorter storage duration on elevated blood lactate levels in children with severe anemia: the TOTAL randomized clinical trial","volume":"314","author":"Dhabangi","year":"2015","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.blre.2019.100593_bb0210","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa1609014","article-title":"Effect of short-term vs. long-term blood storage on mortality after transfusion","volume":"375","author":"Heddle","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.blre.2019.100593_bb0215","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa1414219","article-title":"Effects of red-cell storage duration on patients undergoing cardiac surgery","volume":"372","author":"Steiner","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.blre.2019.100593_bb0220","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMoa1500704","article-title":"Age of transfused blood in critically ill adults","volume":"372","author":"Lacroix","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.blre.2019.100593_bb0225","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1111\/trf.14640","article-title":"Age of transfused blood in critically ill adult trauma patients: a prespecified nested analysis of the age of blood evaluation randomized trial","volume":"58","author":"Green","year":"2018","journal-title":"Transfusion"},{"issue":"14","key":"10.1016\/j.blre.2019.100593_bb0230","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/2012.jama.11953","article-title":"Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial","volume":"308","author":"Fergusson","year":"2012","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb0235","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/vox.12495","article-title":"Mortality outcomes in patients transfused with fresher versus older red blood cells: a meta-analysis","volume":"112","author":"Chai-Adisaksopha","year":"2017","journal-title":"Vox Sang"},{"issue":"19","key":"10.1016\/j.blre.2019.100593_bb0240","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1001\/jama.2016.9185","article-title":"Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage","volume":"316","author":"Carson","year":"2016","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.blre.2019.100593_bb0245","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1016\/S2352-3026(17)30169-2","article-title":"Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial","volume":"4","author":"Cook","year":"2017","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.blre.2019.100593_bb0250","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M16-1415","article-title":"Length of storage of red blood cells and patient survival after blood transfusion: a binational cohort study","volume":"166","author":"Halmin","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2019.100593_bb0255","article-title":"Transfusion of red blood cells stored for shorter versus longer duration for all conditions","volume":"12","author":"Shah","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.blre.2019.100593_bb0265","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bjh.12143","article-title":"Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients","volume":"160","author":"Retter","year":"2013","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0270","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.13853","article-title":"Guidelines for the diagnosis and management of adult aplastic anaemia","volume":"172","author":"Killick","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb0275","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.tracli.2017.05.016","article-title":"Management of delayed hemolytic transfusion reaction in sickle cell disease: prevention, diagnosis, treatment","volume":"24","author":"Pirenne","year":"2017","journal-title":"Transfus Clin Biol"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0280","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/trf.15004","article-title":"Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III)","volume":"59","author":"Karafin","year":"2019","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.blre.2019.100593_bb0285","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.15182","article-title":"Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database","volume":"181","author":"Karafin","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0290","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.tmrv.2014.11.004","article-title":"Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia","volume":"29","author":"Nahirniak","year":"2015","journal-title":"Transfus Med Rev"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb0295","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2017.76.1734","article-title":"Platelet transfusion for patients with cancer: american society of clinical oncology clinical practice guideline update","volume":"36","author":"Schiffer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb0300","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2141.2012.09190.x","article-title":"Role of granulocyte\/neutrophil transfusions for haematology\/oncology patients in the modern era","volume":"158","author":"Strauss","year":"2012","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.blre.2019.100593_bb0305","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1111\/trf.14789","article-title":"The epidemiology of bacterial culture-positive and septic transfusion reactions at a large tertiary academic center: 2009 to 2016","volume":"58","author":"Erony","year":"2018","journal-title":"Transfusion"},{"issue":"25","key":"10.1016\/j.blre.2019.100593_bb0310","doi-asserted-by":"crossref","first-page":"718","DOI":"10.15585\/mmwr.mm6725a4","article-title":"Fatal sepsis associated with bacterial contamination of platelets \u2013 Utah and California, August 2017","volume":"67","author":"Horth","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.blre.2019.100593_bb0315","series-title":"Bacterial Detection Testing by Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion","year":"2018"},{"key":"10.1016\/j.blre.2019.100593_bb0320","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/asheducation-2008.1.198","article-title":"New strategies for the optimal use of platelet transfusions","author":"Blajchman","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0325","doi-asserted-by":"crossref","first-page":"20","DOI":"10.21307\/immunohematology-2019-314","article-title":"ABO and platelet transfusion therapy","volume":"23","author":"Cooling","year":"2007","journal-title":"Immunohematology"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0330","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1537-2995.2008.02011.x","article-title":"Platelet ABO matters","volume":"49","author":"Kaufman","year":"2009","journal-title":"Transfusion"},{"issue":"19","key":"10.1016\/j.blre.2019.100593_bb0335","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1212772","article-title":"A no-prophylaxis platelet-transfusion strategy for hematologic cancers","volume":"368","author":"Stanworth","year":"2013","journal-title":"N Engl J Med"},{"issue":"9850","key":"10.1016\/j.blre.2019.100593_bb0340","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(12)60689-8","article-title":"Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study","volume":"380","author":"Wandt","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2019.100593_bb0345","article-title":"A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation","volume":"9","author":"Crighton","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb0350","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011771","article-title":"Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia","volume":"2015","author":"Estcourt","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.blre.2019.100593_bb0355","article-title":"Prophylactic platelet transfusions prior to surgery for people with a low platelet count","volume":"9","author":"Estcourt","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.blre.2019.100593_bb0360","article-title":"Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia","volume":"4","author":"Estcourt","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.blre.2019.100593_bb0365","article-title":"Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders","volume":"5","author":"Malouf","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb0370","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.hoc.2016.01.002","article-title":"Platelet transfusions in patients with hypoproliferative thrombocytopenia: conclusions from clinical trials and current controversies","volume":"30","author":"Crighton","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10","key":"10.1016\/j.blre.2019.100593_bb0375","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/trf.12646","article-title":"Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial","volume":"54","author":"Stanworth","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2019.100593_bb0380","article-title":"Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation","volume":"10","author":"Estcourt","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.blre.2019.100593_bb0385","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJMoa0904084","article-title":"Dose of prophylactic platelet transfusions and prevention of hemorrhage","volume":"362","author":"Slichter","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100593_bb0390","article-title":"Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation","volume":"11","author":"Estcourt","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212191","article-title":"Platelet count abnormalities and peri-operative outcomes in adults undergoing elective, non-cardiac surgery","volume":"14","author":"Weil","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb0400","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjh.14423","article-title":"Guidelines for the use of platelet transfusions","volume":"176","author":"Estcourt","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb0405","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M14-1589","article-title":"Platelet transfusion: a clinical practice guideline from the AABB","volume":"162","author":"Kaufman","year":"2015","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb0410","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccc.2005.04.003","article-title":"Bleeding in cardiac surgery: its prevention and treatment \u2013 an evidence-based review","volume":"21","author":"Whitlock","year":"2005","journal-title":"Crit Care Clin"},{"issue":"48","key":"10.1016\/j.blre.2019.100593_bb0415","first-page":"809","article-title":"Platelet transfusion in hematology, oncology and surgery","volume":"111","author":"Wandt","year":"2014","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0420","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/rth2.12004","article-title":"The association between platelet transfusions and bleeding in critically ill patients with thrombocytopenia","volume":"1","author":"Arnold","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"10.1016\/j.blre.2019.100593_bb0425","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2013-02-435693","article-title":"Platelet transfusions for critically ill patients with thrombocytopenia","volume":"123","author":"Lieberman","year":"2014","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.blre.2019.100593_bb0430","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1182\/blood-2018-11-833996","article-title":"Prevention of transfusion-transmitted infections","volume":"133","author":"Busch","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0435","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/trf.12791","article-title":"Transfusion-related adverse events in the Platelet Dose study","volume":"55","author":"Kaufman","year":"2015","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0440","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.0041-1132.2004.00609.x","article-title":"Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs","volume":"44","author":"King","year":"2004","journal-title":"Transfusion"},{"issue":"17","key":"10.1016\/j.blre.2019.100593_bb0445","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2018-10-860809","article-title":"Transfusion-associated circulatory overload and transfusion-related acute lung injury","volume":"133","author":"Semple","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0450","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/ajcp\/aqx151","article-title":"Prophylactic preprocedure platelet transfusion is associated with increased risk of thrombosis and mortality","volume":"149","author":"Schmidt","year":"2017","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0455","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cgh.2016.07.017","article-title":"No benefit from platelet transfusion for gastrointestinal bleeding in patients taking antiplatelet agents","volume":"15","author":"Zakko","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10038","key":"10.1016\/j.blre.2019.100593_bb0460","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/S0140-6736(16)30392-0","article-title":"Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial","volume":"387","author":"Baharoglu","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb0465","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1807320","article-title":"Randomized trial of platelet-transfusion thresholds in neonates","volume":"380","author":"Curley","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2019.100593_bb0470","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/trf.13996","article-title":"Preprocedural platelet transfusion for patients with thrombocytopenia undergoing interventional radiology procedures is not associated with reduced bleeding complications","volume":"57","author":"Warner","year":"2017","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0475","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.athoracsur.2008.04.051","article-title":"Platelet transfusion in cardiac surgery does not confer increased risk for adverse morbid outcomes","volume":"86","author":"McGrath","year":"2008","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"10.1016\/j.blre.2019.100593_bb0480","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/trf.14561","article-title":"Platelet transfusion is not associated with increased mortality or morbidity in patients undergoing cardiac surgery","volume":"58","author":"Ninkovic","year":"2018","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0485","first-page":"132","article-title":"Recommendations for the transfusion of plasma and platelets","volume":"7","author":"Liumbruno","year":"2009","journal-title":"Blood Transfus"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0490","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/trf.13356","article-title":"Five-day stability of thawed plasma: solvent\/detergent-treated plasma comparable with fresh-frozen plasma and plasma frozen within 24 hours","volume":"56","author":"Neisser-Svae","year":"2016","journal-title":"Transfusion"},{"issue":"12","key":"10.1016\/j.blre.2019.100593_bb0495","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1111\/j.1537-2995.2008.01913.x","article-title":"Coagulation factor levels in plasma frozen within 24 hours of phlebotomy over 5 days of storage at 1 to 6 degrees C","volume":"48","author":"Yazer","year":"2008","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0500","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2141.2004.04972.x","article-title":"Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant","volume":"126","author":"O'Shaughnessy","year":"2004","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb0505","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.hoc.2016.01.003","article-title":"Assessing the rationale and effectiveness of frozen plasma transfusions: an evidence-based review","volume":"30","author":"Tinmouth","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0510","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1537-2995.2010.02798.x","article-title":"The use of fresh-frozen plasma in England: high levels of inappropriate use in adults and children","volume":"51","author":"Stanworth","year":"2011","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0515","doi-asserted-by":"crossref","first-page":"R108","DOI":"10.1186\/cc10129","article-title":"A national study of plasma use in critical care: clinical indications, dose and effect on prothrombin time","volume":"15","author":"Stanworth","year":"2011","journal-title":"Crit Care"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb0520","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/01.moh.0000245688.47333.b6","article-title":"Should plasma be transfused prophylactically before invasive procedures?","volume":"13","author":"Holland","year":"2006","journal-title":"Curr Opin Hematol"},{"issue":"9","key":"10.1016\/j.blre.2019.100593_bb0525","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1537-2995.2005.00546.x","article-title":"Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review","volume":"45","author":"Segal","year":"2005","journal-title":"Transfusion"},{"issue":"8","key":"10.1016\/j.blre.2019.100593_bb0530","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1537-2995.2006.00891.x","article-title":"Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities","volume":"46","author":"Abdel-Wahab","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2019.100593_bb0535","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010654","article-title":"Plasma transfusion strategies for critically ill patients","volume":"12","author":"Karam","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.blre.2019.100593_bb0540","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/j.1537-2995.2011.03515.x","article-title":"Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials","volume":"52","author":"Yang","year":"2012","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.blre.2019.100593_bb0545","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1213\/ANE.0000000000001730","article-title":"Prophylactic plasma transfusion is not associated with decreased red blood cell requirements in critically ill patients","volume":"124","author":"Warner","year":"2017","journal-title":"Anesth Analg"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0550","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/trf.14988","article-title":"Higher intraoperative plasma transfusion volumes are associated with inferior perioperative outcomes","volume":"59","author":"Warner","year":"2019","journal-title":"Transfusion"},{"issue":"8","key":"10.1016\/j.blre.2019.100593_bb0555","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.mayocp.2016.05.010","article-title":"Prophylactic plasma transfusion before interventional radiology procedures is not associated with reduced bleeding complications","volume":"91","author":"Warner","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0560","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjh.15167","article-title":"British Society of Haematology Guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: their handling and use in various patient groups in the absence of major bleeding","volume":"181","author":"Green","year":"2018","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb0565","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/j.1537-2995.2010.02632.x","article-title":"Evidence-based practice guidelines for plasma transfusion","volume":"50","author":"Roback","year":"2010","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb0570","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/S2352-3026(15)00283-5","article-title":"Prophylactic plasma transfusion for surgical patients with abnormal preoperative coagulation tests: a single-institution propensity-adjusted cohort study","volume":"3","author":"Jia","year":"2016","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb0575","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/j.1537-2995.2010.02630.x","article-title":"The effect of plasma transfusion on morbidity and mortality: a systematic review and meta-analysis","volume":"50","author":"Murad","year":"2010","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb0580","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/bja\/aew343","article-title":"Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial","volume":"117","author":"Nascimento","year":"2016","journal-title":"Br J Anaesth"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb0585","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/bja\/aeu158","article-title":"Cryoprecipitate therapy","volume":"113","author":"Nascimento","year":"2014","journal-title":"Br J Anaesth"},{"issue":"9","key":"10.1016\/j.blre.2019.100593_bb0590","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2014-08-552000","article-title":"How I use fibrinogen replacement therapy in acquired bleeding","volume":"125","author":"Levy","year":"2015","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2019.100593_bb0595","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1182\/bloodadvances.2018022632","article-title":"Coagulation parameters during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study","volume":"2","author":"Gillissen","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0600","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/bjh.14804","article-title":"Fibrinogen concentration and use of fibrinogen supplementation with cryoprecipitate in patients with critical bleeding receiving massive transfusion: a bi-national cohort study","volume":"179","author":"McQuilten","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2019.100593_bb0605","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.injury.2016.11.021","article-title":"Fibrinogen is an independent predictor of mortality in major trauma patients: a five-year statewide cohort study","volume":"48","author":"McQuilten","year":"2017","journal-title":"Injury"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0610","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.athoracsur.2016.01.005","article-title":"Fibrinogen levels after cardiac surgical procedures: association with postoperative bleeding, trigger values, and target values","volume":"102","author":"Ranucci","year":"2016","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0615","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/bja\/aev134","article-title":"Early cryoprecipitate for major haemorrhage in trauma: a randomised controlled feasibility trial","volume":"115","author":"Curry","year":"2015","journal-title":"Br J Anaesth"},{"issue":"1 Suppl 1","key":"10.1016\/j.blre.2019.100593_bb0620","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1097\/TA.0b013e31828fa3ed","article-title":"Cryoprecipitate use in the PROMMTT study","volume":"75","author":"Holcomb","year":"2013","journal-title":"J Trauma Acute Care Surg"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb0625","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.1987.tb02359.x","article-title":"Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient","volume":"67","author":"Ciavarella","year":"1987","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0630","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/bja\/aes227","article-title":"Supplementation of fibrinogen in acquired bleeding disorders: experience, evidence, guidelines, and licences","volume":"109","author":"Ranucci","year":"2012","journal-title":"Br J Anaesth"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb0635","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1365-3148.2011.01098.x","article-title":"Cryoprecipitate transfusion: assessing appropriateness and dosing in trauma","volume":"21","author":"Nascimento","year":"2011","journal-title":"Transfus Med"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0640","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/cc8943","article-title":"Management of bleeding following major trauma: an updated European guideline","volume":"14","author":"Rossaint","year":"2010","journal-title":"Crit Care"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2019.100593_bb0645","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0049-3848(12)70004-X","article-title":"The role of fibrinogen: a new paradigm in the treatment of coagulopathic bleeding","volume":"128","author":"Sorensen","year":"2011","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.blre.2019.100593_bb0650","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1365-3148.2012.01158.x","article-title":"Cryoprecipitate for transfusion: which patients receive it and why? A study of patterns of use across three regions in England","volume":"22","author":"Tinegate","year":"2012","journal-title":"Transfus Med"},{"issue":"18","key":"10.1016\/j.blre.2019.100593_bb0655","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood-2014-10-512608","article-title":"How I treat postpartum hemorrhage","volume":"125","author":"Pavord","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0660","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1186\/cc12685","article-title":"Management of bleeding and coagulopathy following major trauma: an updated European guideline","volume":"17","author":"Spahn","year":"2013","journal-title":"Crit Care"},{"issue":"4","key":"10.1016\/j.blre.2019.100593_bb0665","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/hep.26359","article-title":"Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012","volume":"57","author":"Runyon","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.blre.2019.100593_bb0670","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jhep.2016.12.003","article-title":"EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure","volume":"66","author":"European Association for the Study of the Liver; Electronic address: easloffice@easloffice.eu; Clinical practice guidelines panel","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb0675","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/adc.48.6.483","article-title":"Acute anaphylaxis, pulmonary oedema, and intravascular haemolysis due to cryoprecipitate","volume":"48","author":"Burman","year":"1973","journal-title":"Arch Dis Child"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0680","first-page":"77","article-title":"Incidence of allo-immunization and allergic reactions to cryoprecipitate in haemophilia","volume":"36","author":"McVerry","year":"1979","journal-title":"Vox Sang"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb0685","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1537-2995.1975.15676082234.x","article-title":"An adverse pulmonary reaction to cryoprecipitate in a hemophiliac","volume":"15","author":"Reese","year":"1975","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb0690","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.tmrv.2009.03.001","article-title":"Cryoprecipitate: the current state of knowledge","volume":"23","author":"Callum","year":"2009","journal-title":"Transfus Med Rev"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb0695","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/tme.12380","article-title":"SHOT conference report 2016: serious hazards of transfusion \u2013 human factors continue to cause most transfusion-related incidents","volume":"26","author":"Bolton-Maggs","year":"2016","journal-title":"Transfus Med"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb0700","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.14597","article-title":"Granulocyte transfusions in the management of invasive fungal infections","volume":"177","author":"West","year":"2017","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.blre.2019.100593_bb0705","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1182\/blood-2015-05-645986","article-title":"Efficacy of transfusion with granulocytes from G-CSF\/dexamethasone-treated donors in neutropenic patients with infection","volume":"126","author":"Price","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2019.100593_bb0710","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/bmt.2008.237","article-title":"Randomized phase III study of granulocyte transfusions in neutropenic patients","volume":"42","author":"Seidel","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2019.100593_bb0715","article-title":"Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction","volume":"4","author":"Estcourt","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.blre.2019.100593_bb0720","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.bbmt.2017.07.029","article-title":"Granulocyte transfusions: a critical reappraisal","volume":"23","author":"Valentini","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0725","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/trf.14994","article-title":"The burden of invasive infections in neutropenic patients: incidence, outcomes, and use of granulocyte transfusions","volume":"59","author":"Netelenbos","year":"2019","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0730","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/trf.15025","article-title":"Therapeutic granulocyte transfusions: neutropenic patients with acute leukemia continue to need them \u2013 why are definitive evidence-based practice guidelines elusive?","volume":"59","author":"Strauss","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2019.100593_bb0735","author":"A Open Label"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0740","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.0041-1132.2004.00608.x","article-title":"Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction","volume":"44","author":"Paglino","year":"2004","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0745","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.0041-1132.2003.00518.x","article-title":"The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC","volume":"44","author":"Yazer","year":"2004","journal-title":"Transfusion"},{"issue":"26","key":"10.1016\/j.blre.2019.100593_bb0750","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJM199712253372601","article-title":"Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions","volume":"337","author":"Trial to Reduce Alloimmunization to Platelets Study G","year":"1997","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2019.100593_bb0755","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood.V86.9.3598.bloodjournal8693598","article-title":"A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant","volume":"86","author":"Bowden","year":"1995","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0760","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0887-7963(00)80003-6","article-title":"The cytomegalovirus-\"safe\" blood product: is leukoreduction equivalent to antibody screening?","volume":"14","author":"Preiksaitis","year":"2000","journal-title":"Transfus Med Rev"},{"issue":"5","key":"10.1016\/j.blre.2019.100593_bb0765","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/ajcp\/95.5.609","article-title":"Febrile reactions to platelet transfusions","volume":"95","author":"Mintz","year":"1991","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb0770","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1537-2995.1999.39399219278.x","article-title":"A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets","volume":"39","author":"Heddle","year":"1999","journal-title":"Transfusion"},{"issue":"9S Suppl 1","key":"10.1016\/j.blre.2019.100593_bb0775","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1097\/PCC.0000000000001625","article-title":"Recommendations on selection and processing of RBC components for pediatric patients from the pediatric critical care transfusion and anemia expertise initiative","volume":"19","author":"Zantek","year":"2018","journal-title":"Pediatr Crit Care Med"},{"issue":"8","key":"10.1016\/j.blre.2019.100593_bb0780","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/j.1537-2995.2010.03008.x","article-title":"Prevention of allergic transfusion reactions to platelets and red blood cells through plasma reduction","volume":"51","author":"Tobian","year":"2011","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.blre.2019.100593_bb0785","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1046\/j.1537-2995.2002.00094.x","article-title":"A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets","volume":"42","author":"Heddle","year":"2002","journal-title":"Transfusion"},{"issue":"10","key":"10.1016\/j.blre.2019.100593_bb0790","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJM199409083311001","article-title":"The role of the plasma from platelet concentrates in transfusion reactions","volume":"331","author":"Heddle","year":"1994","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.blre.2019.100593_bb0795","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/trf.12597","article-title":"A comparison of adverse reaction rates for PAS C versus plasma platelet units","volume":"54","author":"Cohn","year":"2014","journal-title":"Transfusio"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb0800","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/trf.12498","article-title":"The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME)","volume":"54","author":"Tobian","year":"2014","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.blre.2019.100593_bb0805","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/trf.14509","article-title":"Transfusion reactions after transfusion of platelets stored in PAS-B, PAS-C, or plasma: a nationwide comparison","volume":"58","author":"van Hout","year":"2018","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.blre.2019.100593_bb0810","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood-2013-09-524348","article-title":"Hepatitis E transmission by transfusion of Intercept blood system-treated plasma","volume":"123","author":"Hauser","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100593_bb0815","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.blre.2018.12.001","article-title":"Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: the dawn of a new era?","volume":"34","author":"Liu","year":"2019","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0820","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/MOH.0000000000000401","article-title":"Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors","volume":"25","author":"Assi","year":"2018","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0825","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/trf.15033","article-title":"Monoclonal anti-CD47 interference in red cell and platelet testing","volume":"59","author":"Velliquette","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2019.100593_bb0830","author":"Organization WH"},{"issue":"4","key":"10.1016\/j.blre.2019.100593_bb0835","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/trf.15134","article-title":"The impact of Daratumumab on transfusion service costs","volume":"59","author":"Cushing","year":"2019","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb0840","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/trf.14021","article-title":"Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy","volume":"57","author":"Anani","year":"2017","journal-title":"Transfusion"},{"issue":"6 Pt 2","key":"10.1016\/j.blre.2019.100593_bb0845","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/trf.13150","article-title":"When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy","volume":"55","author":"Oostendorp","year":"2015","journal-title":"Transfusion"},{"issue":"6 Pt 2","key":"10.1016\/j.blre.2019.100593_bb0850","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0855","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.tracli.2017.12.001","article-title":"Daratumumab: therapeutic asset, biological trap!","volume":"25","author":"Deneys","year":"2018","journal-title":"Transfus Clin Biol"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0860","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/imj.13707","article-title":"Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma","volume":"48","author":"Quach","year":"2018","journal-title":"Intern Med J"},{"issue":"5","key":"10.1016\/j.blre.2019.100593_bb0865","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1111\/trf.15202","article-title":"A blockage monoclonal antibody protocol as an alternative strategy to avoid anti-CD38 interference in immunohematological testing","volume":"59","author":"Chinoca Ziza","year":"2019","journal-title":"Transfusion"},{"issue":"12","key":"10.1016\/j.blre.2019.100593_bb0870","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1111\/trf.14900","article-title":"Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol\/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method)","volume":"58","author":"Hosokawa","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2019.100593_bb0875","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.3389\/fimmu.2018.02616","article-title":"Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies","volume":"9","author":"Lancman","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.blre.2019.100593_bb0880","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CCO.0000000000000468","article-title":"Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience","volume":"30","author":"Folkes","year":"2018","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb0885","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","article-title":"Blocking \u201cdon't eat me\u201d signal of CD47-SIRPalpha in hematological malignancies, an in-depth review","volume":"32","author":"Russ","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2019.100593_bb0890","first-page":"4860284","article-title":"Quality assessment of established and emerging blood components for transfusion","volume":"2016","author":"Acker","year":"2016","journal-title":"J Blood Transfus"},{"issue":"S1","key":"10.1016\/j.blre.2019.100593_bb0895","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/trf.14822","article-title":"Blood products for resuscitation: moving forward by going backward","volume":"59","author":"Ness","year":"2019","journal-title":"Transfusion"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2019.100593_bb0900","first-page":"S190","article-title":"Whole blood for hemostatic resuscitation of major bleeding","volume":"56","author":"Spinella","year":"2016","journal-title":"Transfusion"},{"issue":"8","key":"10.1016\/j.blre.2019.100593_bb0905","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1111\/trf.14779","article-title":"Clinical outcomes among low-titer group O whole blood recipients compared to recipients of conventional components in civilian trauma resuscitation","volume":"58","author":"Seheult","year":"2018","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0910","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.transci.2018.12.012","article-title":"Cold-stored platelets: a product with function optimized for hemorrhage control","volume":"58","author":"Reddoch-Cardenas","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.blre.2019.100593_bb0915","author":"Strandenes"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2019.100593_bb0920","first-page":"S140","article-title":"Comprehensive review of platelet storage methods for use in the treatment of active hemorrhage","volume":"56","author":"Milford","year":"2016","journal-title":"Transfusion"},{"issue":"12","key":"10.1016\/j.blre.2019.100593_bb0925","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1111\/trf.12191","article-title":"Quality of freeze-dried (lyophilized) quarantined single-donor plasma","volume":"53","author":"Bux","year":"2013","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb0930","first-page":"498","article-title":"Novel concepts for damage control resuscitation in trauma","volume":"23","author":"Van","year":"2017","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.blre.2019.100593_bb0935","doi-asserted-by":"crossref","DOI":"10.1111\/tme.12582","article-title":"International haemovigilance: what have we learned and what do we need to do next?","author":"Wood","year":"2019","journal-title":"Transfus Med"},{"key":"10.1016\/j.blre.2019.100593_bb0940","series-title":"Blood Product Safety","author":"Harris","year":"2019"},{"key":"10.1016\/j.blre.2019.100593_bb0945","series-title":"Fatalities reported to FDA following blood collection and transfusion. Annual summary for \ufb01scal year 2017","author":"Food & Drug Administration","year":"2017"},{"key":"10.1016\/j.blre.2019.100593_bb0950","series-title":"The 2018 Annual SHOT Report","author":"Poles","year":"2019"},{"key":"10.1016\/j.blre.2019.100593_bb0955","series-title":"National Healthcare Safety Network Biovigilance Component Hemovigilance Module Surveillance Protocol, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases","year":"2018"},{"issue":"7","key":"10.1016\/j.blre.2019.100593_bb0960","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jama.2009.1198","article-title":"Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial","volume":"302","author":"Bakitas","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb0965","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.2016.70.1474","article-title":"Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Ferrell","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb0970","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/jpm.2013.0250","article-title":"Patterns of hospice use in patients dying from hematologic malignancies","volume":"17","author":"Sexauer","year":"2014","journal-title":"J Palliat Med"},{"issue":"8","key":"10.1016\/j.blre.2019.100593_bb0975","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb0980","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jpainsymman.2014.07.003","article-title":"What is different about patients with hematologic malignancies? A retrospective cohort study of cancer patients referred to a hospice research network","volume":"49","author":"LeBlanc","year":"2015","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"10.1016\/j.blre.2019.100593_bb0985","doi-asserted-by":"crossref","first-page":"E178","DOI":"10.1188\/16.ONF.E178-E187","article-title":"Signs, symptoms, and characteristics associated with end of life in people with a hematologic malignancy: a review of the literature","volume":"43","author":"Button","year":"2016","journal-title":"Oncol Nurs Forum"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb0990","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1200\/JOP.2014.000968","article-title":"Palliative care and hematologic malignancies: old dog, new tricks?","volume":"10","author":"LeBlanc","year":"2014","journal-title":"J Oncol Pract"},{"issue":"26","key":"10.1016\/j.blre.2019.100593_bb0995","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2016.67.8177","article-title":"Barriers to quality end-of-life care for patients with blood cancers","volume":"34","author":"Odejide","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2019.100593_bb1000","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood-2018-03-842575","article-title":"Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia","volume":"132","author":"LeBlanc","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2019.100593_bb1005","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1089\/jpm.2017.0072","article-title":"The prospective evaluation of the net effect of red blood cell transfusions in routine provision of palliative care","volume":"20","author":"To","year":"2017","journal-title":"J Palliat Med"},{"key":"10.1016\/j.blre.2019.100593_bb1010","article-title":"Blood transfusions for anaemia in patients with advanced cancer","volume":"2","author":"Preston","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb1015","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1177\/0269216311434952","article-title":"Blood transfusions in a day hospice setting","volume":"26","author":"Elyan","year":"2012","journal-title":"Palliat Med"},{"issue":"8","key":"10.1016\/j.blre.2019.100593_bb1020","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jama.1972.03200210029007","article-title":"Home transfusions of hemophiliacs","volume":"221","author":"Rabiner","year":"1972","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.blre.2019.100593_bb1025","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1537-2995.1995.35595259158.x","article-title":"Home blood transfusion therapy: a home health agency's 5-year experience","volume":"35","author":"Thompson","year":"1995","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb1030","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0749-2081(05)80151-2","article-title":"Home transfusion for the cancer patient","volume":"6","author":"Rutman","year":"1990","journal-title":"Semin Oncol Nurs"},{"issue":"4","key":"10.1016\/j.blre.2019.100593_bb1035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1246-7820(96)80002-4","article-title":"Transfusion at home? An alternative to the day hospital","volume":"3","author":"Idri","year":"1996","journal-title":"Transfus Clin Biol"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb1040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-3148.2005.00574.x","article-title":"Home blood transfusion: a necessary service development","volume":"15","author":"Ademokun","year":"2005","journal-title":"Transfus Med"},{"key":"10.1016\/j.blre.2019.100593_bb1045","article-title":"Home blood transfusion in France: benefits and development terms","author":"Charron","year":"2018","journal-title":"Transfus Clin Biol"},{"issue":"6","key":"10.1016\/j.blre.2019.100593_bb1050","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2165\/00019053-200119060-00001","article-title":"Developing guidance for budget impact analysis","volume":"19","author":"Trueman","year":"2001","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb1055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tmrv.2008.09.001","article-title":"Cost-effectiveness analysis: what it really means for transfusion medicine decision making","volume":"23","author":"Custer","year":"2009","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.blre.2019.100593_bb1060","doi-asserted-by":"crossref","DOI":"10.7326\/M18-2238","article-title":"Screening the blood supply for Zika virus in the 50 U.S. States and Puerto Rico: a cost-effectiveness analysis","author":"Russell","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2019.100593_bb1065","author":"Excellence NIfHaC"},{"issue":"4","key":"10.1016\/j.blre.2019.100593_bb1070","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1532\/IJH97.04131","article-title":"Economics of pathogen inactivation technology for platelet concentrates in Japan","volume":"80","author":"Staginnus","year":"2004","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb1075","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-3148.2006.00644.x","article-title":"Assessment of the economic value of the INTERCEPT blood system in Belgium","volume":"16","author":"Moeremans","year":"2006","journal-title":"Transfus Med"},{"issue":"9","key":"10.1016\/j.blre.2019.100593_bb1080","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1016\/S0149-2918(03)80288-6","article-title":"Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States","volume":"25","author":"Bell","year":"2003","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb1085","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/trf.12232","article-title":"Reducing the financial impact of pathogen inactivation technology for platelet components: our experience","volume":"54","author":"Girona-Llobera","year":"2014","journal-title":"Transfusion"},{"issue":"10","key":"10.1016\/j.blre.2019.100593_bb1090","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/trf.13149","article-title":"Cost implications of implementation of pathogen-inactivated platelets","volume":"55","author":"McCullough","year":"2015","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.blre.2019.100593_bb1095","first-page":"438","article-title":"Cost-effectiveness analysis of ferric carboxymaltose in pre-operative haemoglobin optimisation in patients undergoing primary knee arthroplasty","volume":"16","author":"Basora","year":"2018","journal-title":"Blood Transfus"},{"issue":"1","key":"10.1016\/j.blre.2019.100593_bb1100","first-page":"16","article-title":"A model-based cost-effectiveness analysis of patient blood management","volume":"17","author":"Kleineruschkamp","year":"2019","journal-title":"Blood Transfus"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb1105","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022352","article-title":"Cost-effectiveness of cell salvage and donor blood transfusion during caesarean section: results from a randomised controlled trial","volume":"9","author":"McLoughlin","year":"2019","journal-title":"BMJ Open"},{"issue":"62","key":"10.1016\/j.blre.2019.100593_bb1110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21620","volume":"21","author":"Walsh","year":"2017","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.blre.2019.100593_bb1115","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.thromres.2018.10.006","article-title":"Blood loss and cost-effectiveness of oral vs intravenous tranexamic acid in primary total hip arthroplasty: a randomized clinical trial","volume":"171","author":"Wu","year":"2018","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.blre.2019.100593_bb1120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/15265161.2016.1276643","article-title":"The precautionary principle and the tolerability of blood transfusion risks","volume":"17","author":"Kramer","year":"2017","journal-title":"Am J Bioeth"},{"issue":"4","key":"10.1016\/j.blre.2019.100593_bb1125","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.tmrv.2011.05.002","article-title":"Proceedings of a consensus conference: risk-based decision making for blood safety","volume":"25","author":"Leach Bennett","year":"2011","journal-title":"Transfus Med Rev"},{"issue":"4","key":"10.1016\/j.blre.2019.100593_bb1130","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1423-0410.2011.01526.x","article-title":"Risk-based decision-making for blood safety: preliminary report of a consensus conference","volume":"101","author":"Stein","year":"2011","journal-title":"Vox Sang"},{"issue":"8","key":"10.1016\/j.blre.2019.100593_bb1135","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/vox.12708","article-title":"Risk-based decision making in transfusion medicine","volume":"113","author":"Leach Bennett","year":"2018","journal-title":"Vox Sang"},{"issue":"8","key":"10.1016\/j.blre.2019.100593_bb1140","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1111\/trf.14912","article-title":"Assessing the risk of Babesia to the United States blood supply using a risk-based decision-making approach: report of AABB's Ad Hoc Babesia Policy Working Group (original report)","volume":"58","author":"Ward","year":"2018","journal-title":"Transfusion"},{"issue":"8","key":"10.1016\/j.blre.2019.100593_bb1145","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/vox.12597","article-title":"Reconsideration of blood donation testing strategy for human T-cell lymphotropic virus in Australia","volume":"112","author":"Styles","year":"2017","journal-title":"Vox Sang"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb1150","first-page":"94","article-title":"Malaria blood safety policy in five non-endemic countries: a retrospective comparison through the lens of the ABO risk-based decision-making framework","volume":"17","author":"O'Brien","year":"2019","journal-title":"Blood Transfus"},{"issue":"8","key":"10.1016\/j.blre.2019.100593_bb1155","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1086\/529143","article-title":"Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets","volume":"46","author":"Jacobs","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.blre.2019.100593_bb1160","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/j.1537-2995.2007.01402.x","article-title":"Platelet bacterial contamination: assessing progress and identifying quandaries in a rapidly evolving field","volume":"47","author":"Yomtovian","year":"2007","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.blre.2019.100593_bb1165","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated health economic evaluation reporting standards (CHEERS)\u2013explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.blre.2019.100593_bb1170","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmrv.2019.01.001","article-title":"Transfusion-transmitted infections reported to the National Healthcare Safety Network Hemovigilance Module","author":"Haass","year":"2019","journal-title":"Transfus Med Rev"},{"issue":"4","key":"10.1016\/j.blre.2019.100593_bb1175","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2015-07-655944","article-title":"Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance","volume":"127","author":"Hong","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2019.100593_bb1180","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/trf.14085","article-title":"Bacterial screening of platelet components by National Health Service Blood and Transplant, an effective risk reduction measure","volume":"57","author":"McDonald","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2019.100593_bb9236","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/ALN.0000000000000463","article-title":"Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management","volume":"122","author":"American Society of Anesthesiologists Task Force on Perioperative Blood Management","year":"2015","journal-title":"Anesthesiology"},{"key":"10.1016\/j.blre.2019.100593_bb9237","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group","year":"2012","journal-title":"Kidney Int Suppl"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X19300621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X19300621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:24:18Z","timestamp":1759436658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X19300621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":237,"alternative-id":["S0268960X19300621"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2019.100593","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of current transfusion therapy and blood banking practices","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2019.100593","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100593"}}